Discontinued — last reported Q2 '23
Business Segments · Amortization
Pharmaceutical — Amortization
Johnson & Johnson Pharmaceutical — Amortization remained flat by 0.0% to $700.00M in Q2 2023 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $700.00M to $700.00M.
Analysis
StatementSegment
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2018
Last reportedQ2 2023
How to read this metric
High amortization levels often reflect significant recent M&A activity or heavy investment in external intellectual property.
Detailed definition
This represents the non-cash expense related to the systematic write-down of intangible assets, such as acquired patents...
Peer comparison
Standard accounting metric for companies with significant acquisition-related intangible assets.
Metric ID:
jnj_segment_pharmaceutical_amortizationHistorical Data
7 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | |
|---|---|---|---|---|---|---|---|
| Value | $800.00M | $800.00M | $800.00M | $700.00M | $700.00M | $700.00M | $700.00M |
| QoQ Change | — | +0.0% | +0.0% | -12.5% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | -12.5% | -12.5% | -12.5% | +0.0% |
Range$700.00M – $800.00M
CAGR-8.5%
Avg YoY Growth-9.4%
Median YoY Growth-12.5%
Current Streak3 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's pharmaceutical — amortization?
- Johnson & Johnson (JNJ) reported pharmaceutical — amortization of $700.00M in Q2 2023.
- How has Johnson & Johnson's pharmaceutical — amortization changed year-over-year?
- Johnson & Johnson's pharmaceutical — amortization decreased by 0.0% year-over-year, from $700.00M to $700.00M.
- What does pharmaceutical — amortization mean?
- The non-cash cost of expensing acquired intangible assets like patents over their useful life.